Human Mimecan (OGN) ELISA kit

Code CSB-EL016314HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
osteoglycin
Alternative Names
Corneal keratan sulfate proteoglycan ELISA Kit; DKFZP586P2421 ELISA Kit; MIME_HUMAN ELISA Kit; Mimecan ELISA Kit; Mimecan proteoglycan ELISA Kit; OG ELISA Kit; OGN ELISA Kit; OIF ELISA Kit; Osteoglycin ELISA Kit; Osteoinductive factor ELISA Kit; SLRR3A ELISA Kit
Abbreviation
OGN
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.156 ng/mL-10 ng/mL
Sensitivity
0.039 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cell Biology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human OGN in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:5Average %96
Range %91-105
1:10Average %95
Range %92-98
1:20Average %87
Range %80-92
1:40Average %99
Range %96-108
Recovery
The recovery of human OGN spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9789-104
EDTA plasma (n=4)9490-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
102.432 2.332 2.382 2.254
51.804 1.704 1.754 1.626
2.51.187 1.287 1.237 1.109
1.250.716 0.726 0.721 0.593
0.6250.447 0.457 0.452 0.324
0.3120.345 0.355 0.350 0.222
0.1560.227 0.237 0.232 0.104
00.129 0.126 0.128  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The Human Mimecan (OGN) ELISA kit is a highly sensitive and reliable tool for quantitative analysis of Mimecan protein levels in human serum, plasma, and tissue homogenates. The kit is designed to measure Mimecan, also known as osteoglycin (OGN), a small leucine-rich proteoglycan involved in various cellular processes, including cell adhesion, differentiation,proliferation and bone formation.

The Human Mimecan (OGN) ELISA kit has a broad detection range of 0.156 ng/mL-10 ng/mL, with a sensitivity of 0.039 ng/mL, ensuring accurate and precise measurements even at low concentrations. The assay principle used is sandwich, which involves the use of two monoclonal antibodies specific to the Mimecan protein.

The assay time for the kit is 1-5 hours, and the sample volume required is 50-100ul. Detection is done at a wavelength of 450 nm, making it easy to read and interpret the results. The kit is suitable for use in cell biology and bone formation research and has been cited in over 2 research articles.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Induces bone formation in conjunction with TGF-beta-1 or TGF-beta-2.
Gene References into Functions
  1. OGN expression is positively associated with CD8+ cell density in colorectal cancer tissue, suggesting a possible influence of OGN expression on tumor reactive T cells in the tumor niche. PMID: 30037719
  2. Results provide evidence that osteoglycin expression is increased in the heart in response to pressure overload and its absence results in increased cardiac inflammation and fibrosis resulting in increased diastolic dysfunction. PMID: 28958774
  3. OGN identified as a novel oncogene in meningioma proliferation. PMID: 28931407
  4. serum osteoglycin is a potential predictor of adverse outcomes in patients with chronic kidney disease. PMID: 28824047
  5. NK cells promote fetal development through the secretion of growth-promoting factors, pleiotrophin and osteoglycin. PMID: 29262349
  6. Increased serum mimecan is associated with poor angiographic coronary collateralization in patients with chronic total occlusion PMID: 27508318
  7. the association of serum OGN and FAM5C levels and muscle mass with bone mineral density (BMD), bone turnover markers, and the presence of vertebral fractures (VFs) in 156 postmenopausal women with type 2 diabetes mellitus, is reported. PMID: 27836731
  8. OGN plays a critical role in negatively regulating ischaemia-induced angiogenesis by inhibiting VEGF-VEGFR2 signalling and thereby attenuating endothelial cells tube formation, proliferation, and migration. PMID: 28069703
  9. The current study discovered a novel 72-kDa chondroitin sulfate-OGN that is specific for innate immune cells. This variant is able to bind and activate TLR4. PMID: 27878326
  10. mimecan is a satiety hormone in adipose tissue, and that mimecan inhibits food intake independently of leptin signaling by inducing IL-1beta and IL-6 expression in the hypothalamus. PMID: 26870797
  11. Increased plasma mimecan levels are independently associated with increased arterial stiffness in hypertensive patients. PMID: 26206738
  12. OIF may be an indicator of the earlier-stage diabetic nephropathy in subjects with type 2 diabetes mellitus PMID: 26045825
  13. OGN might play a role in the development of Ovarian Cancer, and may be a therapeutic target in OC. PMID: 25953442
  14. The lack of the proteoglycan OGN does not affect the progression of atherosclerosis in mice. Possible causes for the absence of phenotype in the Apoe/Ogn double mutants are discussed. PMID: 25463067
  15. Circulating OGN and NGAL/MMP9 complex are promising biomarkers that are expressed in vulnerable atherosclerotic plaques and may have incremental value for prediction of MACE within 1 year after coronary angiography. PMID: 24651681
  16. We found that IGF-2 and IGFBP2 synergistically increased neurite outgrowth via enhanced early signaling through the IGF type 1 receptor. PMID: 23714241
  17. This work provides insight into the regulating mechanism of mimecan in pituitary and suggests that mimecan may be an unidentified pituitary secretory protein, and certain pituitary cells secreting ACTH or GH also secrete mimecan. PMID: 16189248
  18. All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01). PMID: 17895523
  19. High expression in the cochlea may be suggestive of a fundamental role for a transcript in the auditory system PMID: 18243607
  20. Includes the characterization of two human splice variants. PMID: 10373482

Show More

Hide All

Subcellular Location
Secreted, extracellular space, extracellular matrix.
Protein Families
Small leucine-rich proteoglycan (SLRP) family, SLRP class III subfamily
Tissue Specificity
Bone.
Database Links

HGNC: 8126

OMIM: 602383

KEGG: hsa:4969

STRING: 9606.ENSP00000262551

UniGene: Hs.109439

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1